India Pharma Outlook Team | Tuesday, 25 August 2026
The global healthcare landscape continues to shift toward therapies that address rare, complex and life-threatening conditions.
Recent developments from Johnson & Johnson, Dr Reddy’s Laboratories, Emcure Pharmaceuticals, Pulnovo Medical and Bayer highlight this transition.
Together, these moves show how pharmaceutical innovation, generic manufacturing, precision medicine and advanced medical technology can strengthen critical care.
From a first-in-class treatment for a rare blood disorder to a twice-yearly HIV prevention injection and new approaches to pulmonary hypertension and lung cancer, these developments expand options where patients still face major treatment gaps. They also underline the growing importance of collaboration, regulatory support and evidence-driven innovation in improving access to specialized care.
Johnson & Johnson’s Imaavy, or nipocalimab, has secured expanded US FDA approval for warm autoimmune hemolytic anemia (wAIHA). The rare and potentially life-threatening disorder causes the immune system to destroy red blood cells. This can result in severe anemia, fatigue, blood clots, and kidney failure.
The approval covers patients aged 12 years and older who currently receive or previously received steroids. Imaavy blocks a protein that helps keep harmful antibodies in circulation. This mechanism can reduce antibody levels while preserving other immune functions.
"Imaavy was able to demonstrate patients can go down on their steroids and still maintain that clinical response. Those are really important ?advances for patients," said David Lee, Senior Vice President, Global Immunology Therapeutic Area Head at Johnson & Johnson Innovative Medicine.
The regulatory decision draws on a mid-to-late-stage study involving 115 adults. Around three times as many patients receiving Imaavy achieved sustained improvement in hemoglobin levels after 24 weeks compared with placebo. The treatment also showed potential to help patients reduce steroid use while maintaining clinical response.
This development matters because rare diseases often offer limited treatment choices. J&J’s expansion therefore represents more than another indication. It demonstrates how pharmaceutical companies can extend existing innovations into areas with significant unmet medical needs.
Also Read: Why Vaccine Innovation Must Go Beyond Traditional Platforms
India has also moved closer to wider access to lenacapavir, a twice-yearly injectable used to prevent HIV infection. The Central Drugs Standard Control Organization’s subject expert committee recommended waivers for local Phase III and bioequivalence studies for generic versions from Dr Reddy’s Laboratories and Emcure Pharmaceuticals.
The companies will still need to conduct a Phase IV post-marketing efficacy study in India. They must submit the study protocol to CDSCO within three months of receiving marketing authorization.
Lenacapavir addresses an important prevention gap. The committee recognized pre-exposure prophylaxis for adults and adolescents weighing at least 35 kg who face increased risk of sexually acquired HIV as an unmet medical need in India.
The move also highlights the value of licensing partnerships. In 2024, several drugmakers, including four Indian companies, entered non-exclusive, royalty-free licensing agreements with Gilead Sciences to manufacture generic versions for India and 120 low- and middle-income countries. For India, local manufacturing could improve affordability and availability while strengthening the country’s role in global access to advanced medicines.
Critical care innovation extends beyond medicines. Pulnovo Medical has enrolled the first two US patients in its PULSE-LHD trial, which evaluates pulmonary artery denervation (PADN) for pulmonary hypertension associated with left heart disease.
The multicenter, randomized, placebo-procedure-controlled study focuses on combined pre- and post-capillary pulmonary hypertension, classified as WHO Group 2 pulmonary hypertension. Treatment options remain limited for this patient population.
Pulnovo’s PADN system uses a multi-pole radiofrequency ablation catheter to modulate sympathetic nerve activity associated with pulmonary vascular changes and disease progression. The company has already conducted around 1,500 PADN procedures outside the US and holds regulatory approvals across 12 countries and regions for WHO Group 1 pulmonary hypertension.
However, the company stresses that earlier findings do not predict the outcome of the US trial. PADN remains investigational, making the PULSE-LHD study important for generating evidence in a new patient population.
Bayer’s Hyrnuo, or sevabertinib, has received approval from Japan’s Ministry of Health, Labor and Welfare for HER2-mutant unresectable advanced or recurrent non-small cell lung cancer. The oral, reversible small-molecule tyrosine kinase inhibitor offers a first-line option in Japan without restrictions based on treatment line or HER2 mutation subtype.
Data from the global Phase I/II SOHO-01 trial showed a 75.3 per cent objective response rate among 73 previously untreated patients with advanced or recurrent disease. Median duration of response reached 12.2 months, while median progression-free survival stood at 13.5 months.
“The approval of sevabertinib by Japan’s MHLW marks an important advancement for patients with advanced HER2-mutant NSCLC, a patient population that has historically faced limited treatment options,” said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer.
The approval strengthens Bayer’s precision oncology strategy. It also reinforces the importance of timely HER2 testing, since targeted therapies can only deliver their full value when clinicians identify eligible patients.
These four developments reveal a wider shift in healthcare innovation. Pharmaceutical companies increasingly combine novel mechanisms, generic manufacturing, precision medicine and medical technology to address difficult clinical challenges.
The common thread is unmet medical need. Whether the challenge involves a rare blood disorder, HIV prevention, pulmonary hypertension or HER2-mutant lung cancer, innovation must ultimately translate into better access and meaningful patient outcomes.
The next phase of critical care will therefore depend not only on discovering new treatments. It will also depend on regulatory collaboration, clinical evidence, local manufacturing and diagnostic capabilities. Together, these forces can help move specialized therapies from scientific breakthroughs to practical patient care.
.jpg)
